Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Pot firms surge as US move to ease curbs sparks hopes of legalization

Published 08/31/2023, 09:31 AM
Updated 08/31/2023, 11:31 AM
© Reuters. FILE PHOTO: General view shows cannabis plants at Yammouneh in Baalbek district, Lebanon July 4, 2023. REUTERS/Emilie Madi

(Reuters) -Shares of marijuana companies jumped as much as 37% in morning trading on Thursday after a U.S. health agency's proposal to reclassify it as a lower-risk substance boosted expectations of legalization at the federal level.

Nearly 40 U.S. states have legalized marijuana's use in some form but efforts at the federal level have hit a wall, leaving some investors cagey and the sector dependent on non-traditional sources for funding.

"A move to Schedule III would eliminate the onerous tax treatment of U.S. MSOs, and represent a major legitimizing event for the industry that could draw participation from institutions and strategic investors who have hitherto largely been sidelined by its Schedule I status," said Eight Capital analyst Ty Collin.

Shares of cannabis firms Cronos Group (NASDAQ:CRON), OrganiGram Holdings (NASDAQ:OGI), Aurora Cannabis (NASDAQ:ACB), Canopy Growth (NASDAQ:CGC) jumped between 6% and 25%.

Verano Holdings, Green Thumb Industries (OTC:GTBIF), Cresco Labs (OTC:CRLBF) and Curaleaf Holdings (OTC:CURLF) and Goodness Growth rose between 15% and 37%.

Pot stocks tracker AdvisorShares Pure US Cannabis ETF soared nearly 17%. It closed 21.2% higher on Wednesday following the news, clocking its best day since Oct. 6, 2022.

The U.S. Department of Health and Human Services (HHS) has made the recommendation to the Drug Enforcement Agency, which has the final authority on rescheduling and will now initiate its own review.

The SAFE Banking Act, a crucial legislation that would make it easier for the cannabis industry to access banking services, has failed to secure a Senate vote despite the House of Representatives passing it seven times.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"Certainly moving cannabis off of Schedule 1 is the right decision and long overdue. Though a full descheduling would be preferred and likely most appropriate for cannabis," said Patrick Rea, managing director of venture capital firm Poseidon Garden Ventures.

The firm held investments in cannabis retailer and producer Green Thumb, and cannabis data platform Flowhub, according to its website.

Latest comments

Schedule 3 drugs would require a prescription effectively putting dispensaries out of business.
the state got in dirt cheap
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.